- ISIN
- US04683R1068
- CUSIP
- 04683R106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 30, 2020
Highlights
- Market Cap
- $347.68M
- Enterprise Value
- $269.63M
- EPS (TTM)
- -$2.12
- Gross Profit (TTM)
- -$2.52M
- EBITDA (TTM)
- -$185.91M
- Year Range
- $2.78 - $6.45
- Target Price
- $10.00
- ROA (TTM)
- -63.47%
- ROE (TTM)
- -72.53%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AVIR Performance Chart
Atea Pharmaceuticals, Inc. (AVIR) is up 23.0% since the beginning of the year. At $4 per share, AVIR is trading 31.9% below its 52-week high of $6. Investors who bought $1,000 worth of AVIR shares 5 years ago would now be looking at an investment worth $189.
Loading charts...
Returns By Period
Atea Pharmaceuticals, Inc. (AVIR) has returned 22.97% so far this year and 35.08% over the past 12 months.
Atea Pharmaceuticals, Inc.
- 1D
- 0.69%
- 1M
- -0.68%
- YTD
- 22.97%
- 6M
- 38.49%
- 1Y
- 35.08%
- 3Y*
- 3.50%
- 5Y*
- -28.30%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
AVIR Monthly Returns History
Based on dividend-adjusted daily data since Oct 30, 2020, AVIR's average daily return is -0.02%, while the average monthly return is -0.34%.
Historically, 46% of months were positive and 54% were negative. The best month was Jan 2021 with a return of +74.7%, while the worst month was Oct 2021 at -66.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, AVIR closed higher 48% of trading days. The best single day was May 22, 2023 with a return of +36.8%, while the worst single day was Oct 19, 2021 at -66.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.77% | 10.38% | 14.96% | 2.42% | -15.25% | -6.00% | 22.97% | ||||||
| 2025 | -8.66% | -0.98% | -1.32% | -1.34% | 0.68% | 21.21% | 1.11% | -7.69% | -13.69% | 12.07% | -4.62% | 15.16% | 6.57% |
| 2024 | 36.39% | 3.61% | -6.26% | -8.42% | -0.81% | -9.81% | 15.41% | 0.79% | -12.99% | -3.28% | 5.56% | -2.05% | 9.84% |
| 2023 | -3.74% | -23.54% | -5.37% | -2.39% | 22.02% | -6.27% | -8.29% | -2.04% | -10.71% | 8.33% | -8.00% | 2.01% | -36.59% |
| 2022 | -20.13% | -11.20% | 13.88% | -18.70% | 34.24% | -9.90% | 15.49% | -8.54% | -24.13% | 5.45% | -21.83% | 2.56% | -46.20% |
| 2021 | 74.72% | 3.23% | -18.06% | -59.98% | -17.36% | 5.19% | 16.57% | 18.69% | 17.97% | -66.80% | -30.50% | 10.51% | -78.60% |
Benchmark Metrics
Atea Pharmaceuticals, Inc. has an annualized alpha of -18.35%, beta of 0.93, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 30, 2020.
- This stock participated in 81.69% of S&P 500 Index downside but only -43.97% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -18.35%
- Beta
- 0.93
- R²
- 0.05
- Upside Capture
- -43.97%
- Downside Capture
- 81.69%
Return for Risk
Risk / Return Rank
AVIR ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Atea Pharmaceuticals, Inc. (AVIR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AVIR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.31 | ||
| Sortino ratioReturn per unit of downside risk | -1.50 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.37 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | 1.06 | 2.78 | -1.73 |
| Martin ratioReturn relative to average drawdown | 2.20 | 12.44 | -10.23 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Atea Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Atea Pharmaceuticals, Inc. was 97.12%, occurring on May 14, 2025. The portfolio has not yet recovered.
The current Atea Pharmaceuticals, Inc. drawdown is 95.04%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.12%May 2025 | 4y 3mo | — | 5y 4moFeb 2021 - now |
2020 bear market2020 | -22.86%Nov 2020 | 0s | 18d | 18dNov 2020 - Nov 2020 |
2020 correction2020 | -19.37%Dec 2020 | 9d | 12d | 21dNov 2020 - Dec 2020 |
2020 pullback2020 | -7.22%Nov 2020 | 1d | 1d | 2dNov 2020 - Nov 2020 |
2021 pullback2021 | -7.15%Feb 2021 | 0s | 4d | 4dFeb 2021 - Feb 2021 |
Drawdown Indicators
| AVIR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.12% | -56.78% | -40.34% |
Max Drawdown (1Y)Largest decline over 1 year | -33.33% | -9.10% | -24.23% |
Max Drawdown (3Y)Largest decline over 3 years | -44.08% | -18.90% | -25.18% |
Max Drawdown (5Y)Largest decline over 5 years | -94.28% | -25.43% | -68.85% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -95.04% | -1.80% | -93.24% |
Average DrawdownAverage peak-to-trough decline | -85.76% | -10.71% | -75.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.96% | 2.03% | +13.93% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Atea Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Atea Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AVIR in comparison with other companies in the Biotechnology industry. Currently, AVIR has a P/B value of 1.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AVIR
Add Atea Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AVIR